People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xenoport Inc | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2012 |
Dennis M. Fenton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dennis M. Fenton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John G. Freund | 1 | 6 |
| William J. Rieflin | 1 | 4 |
| Jeryl L. Hilleman | 1 | 2 |
| Paul L. Berns | 1 | 2 |
| William G. Harris | 1 | 2 |
| David R. Savello | 1 | 2 |
| Wendell J. Wierenga | 1 | 2 |
| Vincent J. Angotti | 1 | 2 |
| Gianna M. Bosko | 1 | 1 |
| Ronald W. Barrett | 1 | 1 |
| Ernest L. Mario | 1 | 1 |
| Gregory T. Bates | 1 | 1 |
| Catherine J. Friedman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.